INS and thanatophoric dysplasia type 2: CREB1 regulates gluconeogenesis, lipid metabolism, and insulin signaling pathways, and the activity of its transcriptional promoter is associated with the pathogenesis of TD2 [80], adipogenesis [81], and major depressive disorder [82].